AstraZeneca and Bristol Myers Squibb are studying a $400 billion merger
The British pharmaceutical company AstraZeneca is in talks to merge with its American rival Bristol Myers Squibb (BMS), in a deal that would create one of the largest pharmaceutical groups in the world, valued at nearly $400 billion (around €347 billion). According to the Financial Times on Monday, these two companies have been in contact about a possible merger over the past few months. These negotiations could culminate in an agreement in the near future, but they could also be delayed or fail, sources cited by the British newspaper indicate.